



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/823,712	03/30/2001	Gregor Sagner	5443	7485

22829 7590 01/16/2004

ROCHE MOLECULAR SYSTEMS INC  
PATENT LAW DEPARTMENT  
1145 ATLANTIC AVENUE  
ALAMEDA, CA 94501

EXAMINER

CHAKRABARTI, ARUN K

ART UNIT	PAPER NUMBER
----------	--------------

1634

DATE MAILED: 01/16/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

# Office Action Summary

Application No.

09/823,712

Applicant(s)

Sagner

Examiner

Arun Chakrabarti

Art Unit

1634



-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

## Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

## Status

- 1) ☒ Responsive to communication(s) filed on Dec 9, 2003.
- 2a) ☐ This action is FINAL. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11; 453 O.G. 213.

## Disposition of Claims

- 4) ☒ Claim(s) 7-17, 23-26, and 31-39 is/are pending in the application.
- 4a) Of the above, claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☒ Claim(s) 15-17, 23-26, and 31-39 is/are allowed.
- 6) ☒ Claim(s) 7-14 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claims \_\_\_\_\_ are subject to restriction and/or election requirement.

## Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) ☐ The proposed drawing correction filed on \_\_\_\_\_ is: a) ☐ approved b) ☐ disapproved by the Examiner.  
If approved, corrected drawings are required in reply to this Office action.
- 12) ☐ The oath or declaration is objected to by the Examiner.

## Priority under 35 U.S.C. §§ 119 and 120

- 13) ☐ Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  
a) ☐ All b) ☐ Some\* c) ☐ None of:  
1. ☐ Certified copies of the priority documents have been received.  
2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.  
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).  
\*See the attached detailed Office action for a list of the certified copies not received.
- 14) ☐ Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).  
a) ☐ The translation of the foreign language provisional application has been received.
- 15) ☐ Acknowledgement is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

## Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892) 4) ☐ Interview Summary (PTO-413) Paper No(s). \_\_\_\_\_
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948) 5) ☐ Notice of Informal Patent Application (PTO-152)
- 3) ☐ Information Disclosure Statement(s) (PTO-1449) Paper No(s). \_\_\_\_\_ 6) ☒ Other: *Detailed Action*

Art Unit: 1634

## **DETAILED ACTION**

### ***Continued Examination Under 37 CFR 1.114***

1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on December 9, 2003 has been entered.

### ***Specification***

2. Claims 7, 8, 15, 23, 25, and 26 have been amended and new claims 38 and 39 have been added. Claims 7-17, 23-26, and 31-39 are pending in this application.

### ***Claim Rejections - 35 USC § 103***

3. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Art Unit: 1634

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103© and potential 35 U.S.C. 102(f) or (g) prior art under 35 U.S.C. 103(a).

4. Claims 7-14 are rejected under 35 U.S.C. 103(a) over Wittwer et al. (U.S. Patent 6,232,079 B1) (May 15, 2001) in view of Brown et al. (U.S. Patent 6,143, 496) (November 7, 2000) further in view of Haemmerie et al. (U.S. Patent 5,858,658) (January 12, 1999).

Wittwer et al teach a method for determining the efficiency of the amplification (“Note that the amplification efficiency of the CTFR fragment appears greater than the neu fragment. The amplification efficiency can be rigorously determined by integrating the melting peak data as in example 16 (Column 41, last two sentences of the fourth paragraph)” of a target nucleic acid (Abstract, Column 13, line 65 to Column 14, line 32, and Figure 44 and Examples 7, 8, and 16) comprising the steps of:

b) the target nucleic acid is amplified under defined reaction conditions and the amplification is measured in real-time (Figure 44);

c) a defined signal threshold value is set (Figure 44);

Art Unit: 1634

d) determining the cycle number for each dilution at which the signal threshold value is exceeded (Figure 44 and Examples 7, 8, and 16));

e) determining a non-linear continuously differentiable function of a logarithm of copy number of target nucleic acid used for the amplification as a function of the cycle number at which the signal threshold value is exceeded (clearly taught in Figures 15-17 and 42 and Column 33, line 10 to Column 34, line 52); and

f) calculating the amplification efficiency from the function determined in step e) (Figure 44 and Examples 7, 8, and 16).

Wittwer et al teach a method, wherein the amplification efficiency of a certain original amount of target nucleic acid is determined as the negative and reciprocal local first derivative of the continuously differentiable function (Figure 16 and Examples 7, 8, and 16).

Wittwer et al also teach a method for the absolute quantification of a target nucleic acid in a sample (Abstract and Column 12, line 43 to Column 13, line 64) comprising the steps of:

a) determination of the amplification efficiencies of the target nucleic acid and of an internal or external standard (Abstract and Example 16);

b) amplification of the target nucleic acid contained in the sample and of the standard under the same defined reaction conditions (Abstract and Example 16 and Figure 44);

c) measurement of the amplification of the target nucleic acid and standard in real time (Figure 44);

Art Unit: 1634

d) calculation of the original copy number in the sample with the aid of amplification efficiencies determined in step a) (Example 16 and Column 13, lines 29-45).

Wittwer et al. also teach a method, wherein the amplified nucleic acids are detected with the aid of at least one fluorescent-labeled hybridization probe selected from SybreGreen I (Example 14).

Wittwer et al. teach correction of copy number with the aid of amplification efficiencies (Example 16).

Wittwer et al clearly teach calculating the quotients of the function values (copy number) from the target nucleic acid and reference nucleic acid for the sample to be analyzed as well as for the calibrator sample and determination of the ratio of the two quotients as a measure for the original amount of target nucleic acid contained in the sample (Example 16 and Column 8, line 40 to Column 9, line 19).

Wittwer et al do not teach the preparation of different dilutions of the target nucleic acid.

Brown et al teach the preparation of a dilution of the target nucleic acid (Abstract, Example 1, Table 1 and Figure 8);

Wittwer et al do not teach a method, wherein the amplified nucleic acids are detected with the aid of at least one fluorescent-labeled hybridization probe selected from TaqMan probes.

Brown et al teach a method, wherein the amplified nucleic acids are detected with the aid of at least one fluorescent-labeled hybridization probe selected from TaqMan probes (Column 3, lines 25-59).

Art Unit: 1634

It would have been *prima facie* obvious to one having ordinary skill in the art at the time the invention was made to substitute and combine the preparation of a dilution of the target nucleic acid and fluorescent-labeled hybridization probe selected from TaqMan probes of Brown et al in the method of sampling, amplifying and quantifying segment of nucleic acid of Wittwer et al. since Brown et al state, "A need also exists for performing multiple different amplification and detection reactions in parallel on a single specimen and for economizing usage of reagents in the process (Column 4, lines 23-26)". Moreover, Wittwer et al. state, "Thus, with rapid cycling the required times for amplification are reduced approximately 10-fold, and specificity is improved (Column 21, lines 1-3)". An ordinary practitioner would have been motivated to substitute and combine the preparation of a dilution of the target nucleic acid and fluorescent-labeled hybridization probe selected from TaqMan probes of Brown et al in the method of sampling, amplifying and quantifying segment of nucleic acid of Wittwer et al. in order to achieve the express advantages, as noted by Wittwer et al., of a method that allows rapid cycling by which the required times for amplification are reduced approximately 10-fold, and specificity is improved and also to achieve the express advantages, as noted by Brown et al., of a method for performing multiple different amplification and detection reactions in parallel on a single specimen and for economizing usage of reagents in the process.

Wittwer et al. in view of Brown et al do not teach the method, wherein a dilution series of the internal or external standard is prepared along with a dilution series of the target nucleic acid.

Art Unit: 1634

Haemmerie et al. teaches the method, wherein a dilution series of the internal or external standard is prepared along with a dilution series of the target nucleic acid (Abstract, Figures 2A-2I, Column 1, lines 30-44, Column 10, lines 40-54, and Table 2).

It would have been *prima facie* obvious to one having ordinary skill in the art at the time the invention was made to substitute and combine the method, wherein a dilution series of the internal or external standard is prepared along with a dilution series of the target nucleic acid of Haemmerie et al in the method of sampling, amplifying and quantifying segment of nucleic acid of Wittwer et al in view of Brown et al. since Haemmerie et al. states, "This, in turn, implies that the determination of the DNA amount will be the more precise, the more standard dilutions are used (Column 1, lines 42-44)". An ordinary practitioner would have been motivated to substitute and combine the method, wherein a dilution series of the internal or external standard is prepared along with a dilution series of the target nucleic acid of Haemmerie et al. in the method of sampling, amplifying and quantifying segment of nucleic acid of Wittwer et al. in view of Brown et al. in order to achieve the express advantages , as noted by Haemmerie et al., of a method, which implies that the determination of the DNA amount will be the more precise, the more standard dilutions are used

***Allowable Subject Matter***

5. Claims 15-17, 23-26, and 31-39 are allowed.



Art Unit: 1634

***Response to Amendment***

6. In response to amendment, previous 103(a) rejection has been withdrawn. However, new 103 (a) rejection has been included.

***Response to Arguments***

7. Applicant's arguments with respect to claims 7-14 have been considered but are moot in view of the new ground(s) of rejection.

***Conclusion***

8. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Arun Chakrabarti, Ph.D. whose telephone number is (703) 306-5818. This phone number will be changed to (571) 272-0740 on and from January 13, 2004. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Benzion, can be reached on (703) 308-1119. Any inquiry of a general nature or relating to the status of this application should be directed to the Group analyst Chantae Dessau whose telephone number is (703) 605-1237. Papers related to this application may be submitted to Technology Center 1600 by facsimile transmission via the P.T.O. Fax Center located in Crystal Mall 1. The CM1 Fax Center numbers for Technology Center 1600 is (703) 746-4979.

*Arun K. Chakrabarti*  
**ARUN K. CHAKRABARTI**  
Arun Chakrabarti **PATENT EXAMINER**

Patent Examiner

Art Unit 1634

December 23, 2003

*Gary Benzion*  
**GARY BENZION, PH.D.**  
**SUPERVISORY PATENT EXAMINER**  
**TECHNOLOGY CENTER 1600**